PDS Biotechnology Competitors and Similar CompaniesClear all

PDS Biotechnology's competitors and similar companies include PDL BioPharma, EUSA Pharma, Epizyme and X4 Pharmaceuticals.

	PDS Biotechnology PDS Biotechnology is a biopharmaceutical company focused on the development and commercialization of therapies based on the versamune platform.	PDL BioPharma PDL BioPharma, Inc. engages in intellectual property asset management, and patent portfolio and related assets investment activities.	EUSA Pharma EUSA Pharma is a biopharmaceutical company focused on oncology and rare diseases.	Epizyme Epizyme is a clinical stage biopharmaceutical company focusing on treatments for blood cancer and tumors.	X4 Pharmaceuticals X4 Pharmaceuticals (formerly known as Arsanis) is a biopharmaceutical company that provides drug development services.
Founding Date	Founding Date 2005	Founding Date 1986	Founding Date 2015	Founding Date 2007	Founding Date 2010
Type	Type Public	Type Public	Type Private	Type Public	Type Public
Tags	Tags Healthcare biotech oncology pharma	Tags Healthcare biotech oncology pharma	Tags Healthcare biotech oncology pharma	Tags Healthcare biotech oncology pharma	Tags Healthcare biotech drug development pharma therapy
Locations	Locations Princeton, US HQ Florham Park, US	Locations Incline Village, US HQ	Locations Hemel Hempstead, GB HQ	Locations Cambridge, US HQ	Locations Boston, US HQ Wien, AT
Employees	Employees 317% increase	Employees 10521% increase	Employees 965% decrease	Employees 20364% increase	Employees 1005% increase
Valuation ($)	Valuation ($) N/A	Valuation ($) 282.1 m	Valuation ($) N/A	Valuation ($) 250.8 m	Valuation ($) 83.9 m
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $54.8m (FY, 2019)	Revenue (est.) N/A	Revenue (est.) $37.4m (FY, 2021)	Revenue (est.) $6.5m (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods $53.6m (FY, 2019)	Cost of goods N/A	Cost of goods $10.5m (FY, 2021)	Cost of goods $5.8m (FY, 2025)
Gross profit	Gross profit N/A	Gross profit $1.1m (FY, 2019)	Gross profit N/A	Gross profit N/A	Gross profit $743k (FY, 2025)
Net income	Net income ($34.5m) (FY, 2025)	Net income ($70.7m) (FY, 2019)	Net income N/A	Net income ($251.1m) (FY, 2021)	Net income N/A
Funding
Total funding raised	Total funding raised $ 2m	Total funding raised N/A	Total funding raised $ 54.2m	Total funding raised $ 51.5m	Total funding raised $ 64.5m